Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology.
Pouya JoolharzadehMario RodriguezRaja ZaghlolLauren N PedersenJesus JimenezCarmen BergomJoshua D MitchellPublished in: Current cardiology reports (2023)
A recent meta-analysis shows utility for troponin in monitoring patients at risk for CTRC during cancer therapy. The role for natriuretic peptides is less clear but may be useful in patients receiving proteasome inhibitors. Early studies explore use of myeloperoxidase, growth differentiation factor 15, galectin 3, micro-RNA, and others as novel biomarkers in CTRC. Biomarkers have potential to identify subclinical CTRC and may reveal opportunities for early intervention. Further research is needed to elucidate optimal biomarkers and surveillance strategies.
Keyphrases
- systematic review
- cancer therapy
- ejection fraction
- end stage renal disease
- randomized controlled trial
- chronic kidney disease
- newly diagnosed
- public health
- drug delivery
- palliative care
- gene expression
- case control
- case report
- prognostic factors
- genome wide
- single cell
- meta analyses
- risk assessment
- amino acid
- patient reported outcomes
- patient reported